Tarlatamab Combined with Anti-PD-L1 Shows Promising Safety and Unprecedented Overall Survival as First-Line Maintenance Therapy Following Chemo-Immunotherapy in ES-SCLC
In a significant advancement within the landscape of lung cancer therapeutics, novel clinical data unveiled at the 2025 International Association ...